Published in J Clin Microbiol on July 15, 2009
Low-cost tools for diagnosing and monitoring HIV infection in low-resource settings. Bull World Health Organ (2012) 1.21
Systematic review of the performance of HIV viral load technologies on plasma samples. PLoS One (2014) 1.06
Low-cost assays for monitoring HIV infected individuals in resource-limited settings. Indian J Med Res (2011) 1.02
Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay. J Clin Virol (2010) 0.90
HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays. J Clin Virol (2009) 0.85
Factors Influencing Antiretroviral Adherence and Virological Outcomes in People Living with HIV in the Highlands of Papua New Guinea. PLoS One (2015) 0.81
Performance and logistical challenges of alternative HIV-1 virological monitoring options in a clinical setting of Harare, Zimbabwe. Biomed Res Int (2014) 0.81
Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam. BMC Infect Dis (2016) 0.78
Can HIV reverse transcriptase activity assay be a low-cost alternative for viral load monitoring in resource-limited settings? BMJ Open (2016) 0.75
Assessment of the Cavidi ExaVir™ Load assay for monitoring plasma viral load in HIV-2 infected patients. J Clin Microbiol (2017) 0.75
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med (1997) 3.53
HIV-1 viral load assays for resource-limited settings. PLoS Med (2006) 3.30
COBAS AMPLICOR: fully automated RNA and DNA amplification and detection system for routine diagnostic PCR. Clin Chem (1996) 3.17
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med (1997) 2.06
Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clin Infect Dis (2003) 2.00
Comparison of the Roche COBAS Amplicor Monitor, Roche COBAS Ampliprep/COBAS Taqman and Abbott RealTime Test assays for quantification of hepatitis C virus and HIV RNA. Clin Chem Lab Med (2007) 1.90
Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine. Clin Chem Lab Med (2007) 1.47
Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods (2006) 1.31
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA Quantitative assays. J Virol Methods (2006) 1.30
Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol (2007) 1.28
Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J Clin Microbiol (2005) 1.27
HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol (2003) 1.25
Improved HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol (2005) 1.24
Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring. Curr HIV Res (2005) 1.15
Human immunodeficiency virus (HIV) reverse transcriptase activity correlates with HIV RNA load: implications for resource-limited settings. J Clin Microbiol (2005) 1.14
The measurement of HIV-1 viral load in resource-limited settings: how and where? Clin Lab (2007) 1.10
Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings. J Virol Methods (2007) 1.07
Evaluation of the performance of the automated NucliSENS easyMAG and EasyQ systems versus the Roche AmpliPrep-AMPLICOR combination for high-throughput monitoring of human immunodeficiency virus load. J Clin Microbiol (2007) 0.99
Comparative evaluation of the VERSANT HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral load. J Clin Virol (2009) 0.86
HIV-1 viral load assays for resource-limited settings. PLoS Med (2006) 3.30
Reduction in hepatitis C-related liver disease associated with GB virus C in human immunodeficiency virus coinfection. Gastroenterology (2007) 2.86
The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol (2007) 2.41
Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS (2005) 2.06
Tuberculosis and the traveller: evaluating and reducing risk through travel consultation. J Travel Med (2016) 1.97
Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J Infect Dis (2010) 1.80
Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell (2012) 1.71
Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis (2010) 1.70
The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. Curr Med Chem (2002) 1.69
HIV-associated sensory neuropathies. AIDS (2002) 1.65
Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proc Natl Acad Sci U S A (2010) 1.63
HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS (2012) 1.55
Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. AIDS (2002) 1.55
The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages. Rev Med Virol (2003) 1.50
Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One (2010) 1.44
Efficacy of Cyto-Chex blood preservative for delayed manual CD4 testing using Dynal T4 Quant CD4 test among HIV-infected persons in Zambia. J Acquir Immune Defic Syndr (2006) 1.44
Pathogenesis of macrophage tropic HIV-1. Curr HIV Res (2005) 1.43
Blood donation: the new cardiovascular risk factor? Int J Cardiol (2006) 1.39
Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J Clin Virol (2003) 1.35
Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis (2010) 1.33
Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J Clin Microbiol (2005) 1.27
Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS One (2013) 1.24
Point-of-care testing. Curr HIV/AIDS Rep (2011) 1.24
Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals. Am J Pathol (2011) 1.22
Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. J Leukoc Biol (2006) 1.22
CD16+ monocyte subset preferentially harbors HIV-1 and is expanded in pregnant Malawian women with Plasmodium falciparum malaria and HIV-1 infection. J Infect Dis (2007) 1.22
Evaluating new CD4 enumeration technologies for resource-constrained countries. Nat Rev Microbiol (2008) 1.21
Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs. J Leukoc Biol (2006) 1.19
A six-month, supervised, aerobic and resistance exercise program improves self-efficacy in people with human immunodeficiency virus: a randomised controlled trial. Aust J Physiother (2006) 1.18
Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. Retrovirology (2007) 1.17
The importance of monocytes and macrophages in HIV pathogenesis, treatment, and cure. AIDS (2014) 1.17
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis (2013) 1.16
Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals. PLoS One (2011) 1.15
Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring. Curr HIV Res (2005) 1.15
Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol (2012) 1.15
Transendothelial migration of monocytes: the underlying molecular mechanisms and consequences of HIV-1 infection. Curr HIV Res (2005) 1.14
Proline residues within spacer peptide p1 are important for human immunodeficiency virus type 1 infectivity, protein processing, and genomic RNA dimer stability. J Virol (2002) 1.14
Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med (2011) 1.14
HIV and cells of macrophage/dendritic lineage and other non-T cell reservoirs: new answers yield new questions. J Leukoc Biol (2003) 1.13
HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans. J Pain Symptom Manage (2010) 1.12
Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology (2007) 1.09
Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity. J Neurochem (2008) 1.05
Selectively reduced tat mRNA heralds the decline in productive human immunodeficiency virus type 1 infection in monocyte-derived macrophages. J Virol (2002) 1.02
Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. J Virol (2002) 1.01
Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing. Curr HIV/AIDS Rep (2014) 1.01
HIV-1 down-modulates gamma signaling chain of Fc gamma R in human macrophages: a possible mechanism for inhibition of phagocytosis. J Immunol (2002) 1.01
Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1. Curr Med Chem (2005) 1.00
Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia. J Infect Dis (2004) 1.00
HIV-associated sensory neuropathy: risk factors and genetics. Curr Pain Headache Rep (2012) 0.99
Stability of dried blood spots for HIV-1 drug resistance analysis. Curr HIV Res (2010) 0.99
A reliable and inexpensive EasyCD4 assay for monitoring HIV-infected individuals in resource-limited settings. J Acquir Immune Defic Syndr (2006) 0.97
Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. J Clin Virol (2003) 0.96
Can we predict neuropathy risk before stavudine prescription in a resource-limited setting? AIDS Res Hum Retroviruses (2008) 0.93
Use of an HIV-1 reverse-transcriptase enzyme-activity assay to measure HIV-1 viral load as a potential alternative to nucleic acid-based assay for monitoring antiretroviral therapy in resource-limited settings. J Med Microbiol (2007) 0.92
The mechanism underlying defective Fcgamma receptor-mediated phagocytosis by HIV-1-infected human monocyte-derived macrophages. J Immunol (2007) 0.92
Increased glucose metabolic activity is associated with CD4+ T-cell activation and depletion during chronic HIV infection. AIDS (2014) 0.92
Assessment of the low-cost Cavidi ExaVir Load assay for monitoring HIV viral load in pediatric and adult patients. J Acquir Immune Defic Syndr (2009) 0.92
Impaired complement-mediated phagocytosis by HIV type-1-infected human monocyte-derived macrophages involves a cAMP-dependent mechanism. AIDS Res Hum Retroviruses (2006) 0.91
HIV infection and aging of the innate immune system. Sex Health (2011) 0.91
Effects of HIV-1 infection in vitro on transendothelial migration by monocytes and monocyte-derived macrophages. J Leukoc Biol (2009) 0.90
Community acquisition of ESBL-producing Escherichia coli: a growing concern. Med J Aust (2009) 0.90
Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol (2011) 0.89
A novel, rapid method to detect infectious HIV-1 from plasma of persons infected with HIV-1. J Virol Methods (2010) 0.89
Immunological and virological failure after antiretroviral therapy is associated with enhanced peripheral and thymic pathogenicity. J Infect Dis (2003) 0.88
HIV inhibits early signal transduction events triggered by CD16 cross-linking on NK cells, which are important for antibody-dependent cellular cytotoxicity. J Leukoc Biol (2010) 0.88
Human immunodeficiency virus type 1 infection inhibits granulocyte-macrophage colony-stimulating factor-induced activation of STAT5A in human monocyte-derived macrophages. J Virol (2003) 0.87
The international physical activity questionnaire overestimates moderate and vigorous physical activity in HIV-infected individuals compared with accelerometry. J Assoc Nurses AIDS Care (2010) 0.86
Analysis of HIV-1 viral load in seminal plasma samples. J Clin Virol (2003) 0.86
Research bureaucracy in the United Kingdom: research governance is about protection, not convenience. BMJ (2004) 0.86
Isolation of human immunodeficiency virus type 1 from peripheral blood monocytes. Methods Mol Biol (2005) 0.86
Risk of active tuberculosis in immigrants: effects of age, region of origin and time since arrival in a low-exposure setting. Med J Aust (2012) 0.86
Adverse effects of antiretroviral drugs on HIV-1-infected and -uninfected human monocyte-derived macrophages. J Acquir Immune Defic Syndr (2006) 0.86
Normal CD16 expression and phagocytosis of Mycobacterium avium complex by monocytes from a current cohort of HIV-1-infected patients. J Infect Dis (2006) 0.85
Scenario Analysis for Programmatic Tuberculosis Control in Western Province, Papua New Guinea. Am J Epidemiol (2016) 0.85
Endothelial cell activation promotes foam cell formation by monocytes following transendothelial migration in an in vitro model. Exp Mol Pathol (2012) 0.85
Symptomatic and asymptomatic early neurosyphilis in HIV-infected men who have sex with men: a retrospective case series from 2000 to 2007. Sex Health (2011) 0.84
Phagocytic efficiency of monocytes and macrophages obtained from Sydney blood bank cohort members infected with an attenuated strain of HIV-1. J Acquir Immune Defic Syndr (2003) 0.84
The molecular epidemiology of HIV type 1 among Vietnamese Australian injecting drug users in Melbourne, Australia. AIDS Res Hum Retroviruses (2004) 0.83
In vivo replication kinetics of a nef-deleted strain of HIV-1. AIDS (2005) 0.83
Are monocytes the canary in the coal mine for HIV-related atherosclerosis? J Infect Dis (2012) 0.83
First molecular epidemiology study of Mycobacterium tuberculosis in Kiribati. PLoS One (2013) 0.83
HIV reverse transcriptase activity assay: a feasible surrogate for HIV viral load measurement in China. Diagn Microbiol Infect Dis (2010) 0.82
Viremic and Virologically Suppressed HIV Infection Increases Age-Related Changes to Monocyte Activation Equivalent to 12 and 4 Years of Aging, Respectively. J Acquir Immune Defic Syndr (2015) 0.82
A new way of measuring apoptosis by absolute quantitation of inter-nucleosomally fragmented genomic DNA. Nucleic Acids Res (2012) 0.81
Mitochondrial dysfunction in CD4+ lymphocytes from stavudine-treated HIV patients. Mitochondrion (2010) 0.81
Enhanced monocyte Fc phagocytosis by a homologue of interleukin-10 encoded by human cytomegalovirus. Virology (2009) 0.81
Characterization of tetraspanins CD9, CD53, CD63, and CD81 in monocytes and macrophages in HIV-1 infection. J Leukoc Biol (2013) 0.81
Effect of reverse transcriptase inhibitors and mutations on the low-cost Cavidi reverse transcriptase viral load assay. J Acquir Immune Defic Syndr (2009) 0.80
The heterosexual HIV type 1 epidemic in Papua New Guinea is dominated by subtype C. AIDS Res Hum Retroviruses (2007) 0.80
The molecular epidemiology of HIV-1 in South and East Asia. Curr HIV Res (2003) 0.80
Phenotypic characterization of blood monocytes from HIV-infected individuals. Methods Mol Biol (2005) 0.80
Interferon-gamma therapy activates human monocytes for enhanced phagocytosis of Mycobacterium avium complex in HIV-infected individuals. HIV Clin Trials (2004) 0.80